A Study Evaluating TIL therapy (LN-144) With Opdivo (Nivolumab) For The Treatment Of Patients With Metastatic Melanoma.

Trial Profile

A Study Evaluating TIL therapy (LN-144) With Opdivo (Nivolumab) For The Treatment Of Patients With Metastatic Melanoma.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs LN 144 (Primary) ; Nivolumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Jun 2017 According to an Iovance Biotherapeutics media release, Lion Biotechnologies has changed its name to Iovance Biotherapeutics.
    • 14 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top